Efficacy and safety of Kang’ai injection adjunct with TP chemotherapy for the treatment of non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials

Background:Combination therapy with traditional Chinese medicine and chemotherapy was proposed as a therapeutic strategy for non-small cell lung cancer patients.Therefore,we performed a systematic review and metaanalysis of randomized controlled trials to assess effects of this combination therapy on non-small cell lung cancer.To evaluate the efficacy and safety of the Chinese patent medicine Kang’ai injection adjunct with TP chemotherapy in the treatment of non-small cell lung cancer.Methods:A randomized controlled study of the Chinese patent medicine Kang’ai injection adjunct with TP chemotherapy in the databases of China National Knowledge Infrastructure Database,WanFang Database,VIP Database,Sino-Med Database,PUBMED,EMBASE and Cochrane library was searched by computer.The literatures published from the database establishment to July 1,2020 were included in the search scope.After 2 evaluators independently evaluated and cross checked the quality of the study,Revman 5.3 was used to meta analyze the clinical effect of the Chinese patent medicine Kang’ai injection adjunct with TP chemotherapy on patients with non-small cell lung cancer.Results:A total of 1,370 lung cancer patients were included in 20 RCTs.The results of meta-analysis showed that there were significant differences between the 2 groups in clinical efficacy(RR=1.32,95%CI(1.20,1.44)),quality of life(RR=1.44,95%CI(1.32,1.57)),immune function(MD=0.53,95%CI(0.23–0.83)),adverse reactions(RR=0.49,95%CI(0.41,0.58)).Conclusion:The Chinese patent medicine Kang’ai injection adjunct with TP chemotherapy is effective and safe in the treatment of non-small cell lung cancer,and has great prospects for further development.However,the quality of evidence was very low-to-moderate.Considering the poor quality of evidence,we are not very confident in the results.We look forward to more research and update results in the future and improve the evidence quality.

Network pharmacology to predicting therapy targets of traditional Chinese medicine Kang’ai injection on breast cancer

Background:To predict the effective targets of Kang’ai injection and analyze the pharmacological mechanism for the treatment of breast cancer based on the method of network pharmacology.Methods:The Traditional Chinese Medicine Systems Pharmacology database was used to predict the effective components of the Chinese patent medicine Kang’ai injection,and GeneCards database,Online Mendelian Inheritance in Man database and the Therapeutic Target Database were used to predict the therapeutic targets of breast cancer.Cytoscape 3.7.2 was used to construct active ingredient-disease-target network.String database and Cytoscape 3.7.2 software were used to draw the protein-protein interaction network and obtain the core target.Bioconductor and R language were used to analyze the effective action target for gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis.Results:There were 42 effective active ingredients in the Chinese patent medicine Kang’ai injection,which acted on 105 targets,and it had 32 components that acted on 96 targets associated with breast cancer.The target regulates various biological processes such as inflammation,angiogenesis,apoptosis and cell proliferation,and regulates pathways such as PI3K-Akt signaling pathway,MAPK signaling pathway,AGE-RAGE signaling pathway in diabetic complications and thyroid hormone signaling pathway through gene ontology and Kyoto Encyclopedia of Genes and Genomes analysis.Conclusion:The treatment of breast cancer with the Chinese patent medicine Kang’ai injection is a complex mechanism process with multiple targets,multiple pathways,and multiple choices,which provides a theoretical basis for the further extraction of effective components in the treatment of breast cancer.

Meta-analysis of therapy of Kang’ai injection combined with chemotherapy in the treatment of non-small cell lung cancer

Objective:To compare the safety and efficacy of Kang’ai injection combined with chemotherapy and chemotherapy alone in the treatment of non-small cell lung cancer.Methods:The related control and randomized studies from 1966 to October 01,2022,were retrieved in the following databases:China National Knowledge Infrastructure,Wanfang databases,Value In Paper,SinoMed,PubMed,Embase and Cochrane Library.A comprehensive literature search was conducted in 7 electronic databases identifying all the relevant randomized controlled trials.Cochrane handbook 5.2.3 was applied to evaluate the quality of included trials,and the RevMan 5.3 software was used to analyze data and assess the publication bias.Results:From the 16 studies reviewed,a total of 1,398 patients were included.Compared with docetaxel+cis-platinum chemotherapy alone,Kang’ai injection combined with docetaxel+cis-platinum chemotherapy showed significant effects in improving clinical response rate(RR:1.40,95%confidence interval(CI)(1.25,1.58)),quality of life score(Karnofsky score)(RR:1.53,95%CI(1.32,1.78)),traditional Chinese medicine syndrome(RR:2.01,95%CI(1.43,2.83))and safety(RR:0.62,95%CI(0.54,0.71)),the differences were statistically significant.Conclusion:Kang’ai injection may increase the therapeutic effectiveness,improve the quality of life,and reduce the toxicity of chemotherapy in patients with non-small cell lung cancer.These results require confirmation by further rigorously designed randomized controlled trials(PROSPERO registration number:CRD42020176917).

Effect of Kang’ai Injection (康艾注射液) on Serum Level of Soluble Interleukin-2 Receptor and Vascular Endothelial Growth Factor in Patients with Esophageal Carcinoma during Radiotherapy

Objective： To observe the effect of Kang＇ai Injection （康艾注射液, KAI） on serum level of soluble interleukin-2 receptor （sIL-2R） and vascular endothelial growth factor （VEGF） in patients with esophageal carcinoma （EC） during radiotherapy （RT）, and to investigate its synergistic effect with RT and its influence on immunological function of the body. Methods： One hundred and seventy patients with EC, who had missed the chance of surgical operational therapy, were assigned to the treated group （90 cases） and the RT group （80 cases）, and at the same time a control group consisting of 80 inpatients without tumors was set up. Patients in the RT group were treated with RT alone but KAI was given additionally to those in the treated group, with 50 ml given once per day via intravenous dripping, 15 days as one course, and 2 courses administered in total. The immediate therapeutic efficacy and changes of serum slL-2R and VEGF levels were observed, and the effect of KAI on patients＇ quality of life （QOF） was evaluated by Karnofsky scoring. Results： In 16 patients of the treated group it was completely remission （OR）, in 54 partially remission （PR）, in 18 it was stabilized disease （SD） and in 2 progressive disease （PD）, with the total effective rate （CR ＋ PR） as 77.8%, while in those of the control group it was 12, 46, 18, 4 and 72.5%, respectively, the immediate therapeutic efficacy in the treated group was somewhat better than that in the RT group, but showed no statistical significance （P〉0.05）. Serum levels of slL-2R and VEGF in all the patients before treatment were higher than those in the control group, which were decreased after treatment in both groups （P〈0.05）, but the improvement in the treated group was better than that in the RT group, showing significant difference （P〈0.05）, and patients＇ QOF improved more significantly in the former as well （62.2 % vs 40.0%, P〈 0.05）. Conclusion： KAI in combination with RT in treating patients with EC could enhance the immunological function of patients, improve their QOF and enhance their sensitivity to RT.

Efficacy of intra- tumor injection of Kang-Lai-Te in treating transplanted hepatoma in rats

BACKGROUND: Non-operative therapy takes an impor- tant position in comprehensive therapy of liver cancer. De- spite some effects by using ethanol, acetic acid and heat sa- line for intra-tumor injection in the treatment of liver canc- er, it is difficult to attain a complete cure but bring about injury to the liver to some extent. Hence, searching for other drugs for the local treatment of liver tumor is an im- portant option. This study was designed to set up rat mo- dels of transplanted liver cancer, intra-tumor injection of Kang-Lai-Te (KLT), and negative control (saline) and positive control (ethanol). The effect of intra-tumor injec- tion of KLT in treating transplanted hepatoma in rats and its advantages and disadvantages were assessed and the pos- sibility of its use in treating patients with liver cancer was evaluated. METHODS: Forty rats were divided into 4 groups ( G1, G2, G3 and G4, 10 rats in each group). Different drugs were injected into their implanted hepatoma (G1 with 0.2 ml saline as control, G2 with 10 mg KLT, G3 with 20 mg KLT, G4 with 0.2 ml ethanol). After 3 and 8 days, the hepa- toma volume (HV), the serum levels of albumin, alanine aminotransferase(ALT), aspartate aminotransferase alkaline phosphatase( ALP) and creatinine, as well as the expression of proliferation cell nuclear antigen (PCNA) in hepatoma were detected. RESULTS: After 3 days, the HVs were smaller in G3 and G4 than in G1 (P <0.05), the serum levels of albumin were higher in G2 and G3 than in Gl and G4 (P <0.05), the se- rum levels of ALT and AST were lower in G2 and G3 than in G4 (P<0.05), the serum levels of ALP was lower in G2 and G3 than in Gl and G4 (P <0. 05), the PCNA labeling indexes (PCNA LI) were lower in G2 and G3 than in Gl and GA (P <0.05). After 8 days, the HVs were smaller in G2, G3 and G4 than in Gl (P <0.05), and the differences of HVs among G2, G3 and G4 were not significant. The serum levels of ALP were lower in G1, G2 and G3 than in G4 (P <0.05), and the PCNA LI were lower in G3 than in Gl andG4 (P<0.05). CONCLUSION: Intra-tumor injection of KLT into implan- ted hepatoma is evidently effective, but it is less effective than ethanol. The effect of KLT on liver function is markedly lower than that of ethanol.

Effect of Kang Ai injection + conventional chemotherapy on tumor markers, apoptotic molecules and immune response in patients with advanced NSCLC

Objective: To study the effects of Kang Ai injection + conventional chemotherapy on tumor markers, apoptotic molecules and immune response in patients with advanced non-small cell lung cancer (NSCLC). Methods: Patients diagnosed as advanced NSCLC in our hospital during March 2015 - October 2017 were randomly divided into the experimental group receiving Kang Ai injection + conventional chemotherapy and the control group receiving conventional chemotherapy. The contents of tumor markers, apoptotic molecules and immunologic cytokines in serum and the contents of immune cells in peripheral blood were determined before and after chemotherapy. Results: after chemotherapy, the content of CEA, CYFRA21-1, SCC-Ag, GDF15 and Livin in the serum of the two groups decreased significantly, and the content of PDCD5, P53 and Bax increased significantly, and the content of CEA, CYFRA21-1, SCC-Ag, GDF15, Livin in the serum of the experimental group were lower than those of the control group, and the content of PDCD5, P53 and Bax were higher than those of the control group;the content of CD3+ and CD4+ cells in peripheral blood and the content of IFN-γ, IL-2 in serum of control group significantly decreased, whereas the content of CD8+ cells in peripheral blood and the content of IL-4, IL-5 in serum significantly increased after chemotherapy;while the content of CD3+ and CD4+ cells in peripheral blood and the content of IFN-γ, IL-2 in serum of experimental group significantly increased, whereas the content of CD8+ cells in peripheral blood and the content of IL-4, IL-5 in serum significantly decreased after chemotherapy. Conclusion: Kang Ai injection + conventional chemotherapy in the treatment of advanced NSCLC can more significantly decrease the serum tumor markers, regulate the secretion of apoptotic molecules and anti-tumor immune response than conventional chemotherapy.

Clinical Observation on the Improved Short-Term Effects of Anti-Tumor Purified Chinese Medicine Injection Ai-Jing for 138 Cases with Malignant Tumors

The subjects of this study were to observe the improved short-term effects of anti-tumor purified Chinese medicine injection Ai-Jing for 138 cases with malignant tumors. This was a multi-center clinical study, and a total of 138 patients included 96 males and 42 females, with the age from 60 to 76 years. Ai-Jing has obtained the Chinese invention patent since 2008 (ZL991-03528.3). A novel technique acupoint injection method was adopted. Except for lung cancer, patients with other malignant tumors were injected once every other day, 2 ml each time. A course of treatment needs 6 Ai-Jing injections, lung cancer patients need 10 - 20 Ai-Jing injections. At the same time, patients were treated with traditional medicine decoction. Due to the limited number of cases, cure rate, recovery rate and remission rate were calculated as a whole, respectively 18.12%, 44.20% and 32.15%. All the invalid patients were lung cancer, accounting for 16.67% of the patients treated with lung cancer, and the total treatment inefficiency was 6.52%. Conclusion: Chinese Medicine Injection Ai-Jing extracts the effective components of anti-cancer and tumorigenesis, and has the effects of anti-cancer and tumorigenesis, anti-inflam-matory and analgesic, and repairing body damage, with small toxic and side effects and low cost.

Study and Analysis of Defect Amplification Index in Technology Variant Business Application Development through Fault Injection Patterns

Software reliability for business applications is becoming a topic of interest in the IT community. An effective method to validate and understand defect behaviour in a software application is Fault Injection. Fault injection involves the deliberate insertion of faults or errors into software in order to determine its response and to study its behaviour. Fault Injection Modeling has demonstrated to be an effective method for study and analysis of defect response, validating fault-tolerant systems, and understanding systems behaviour in the presence of injected faults. The objectives of this study are to measure and analyze defect leakage;Amplification Index (AI) of errors and examine “Domino” effect of defects leaked into subsequent Software Development Life Cycle phases in a business application. The approach endeavour to demonstrate the phasewise impact of leaked defects, through causal analysis and quantitative analysis of defects leakage and amplification index patterns in system built using technology variants (C#, VB 6.0, Java).

应用组织芯片技术检测KAI1、MRP-1、FAK蛋白在肺癌组织中的表达

背景与目的:肿瘤的发生发展、浸润转移与多基因改变密切相关。目前Kang-ai-1(KAI1)、移动相关蛋白(motility-relatedprotein-1,MRP-1)和局部粘着斑激酶(focaladhesionkinase,FAK)3种基因在肺癌中的共同作用研究较少。本研究旨在探讨这3种基因的蛋白产物在肺癌发生发展中的作用及其在肿瘤诊断和预后判断中的价值。方法:应用免疫组化SP方法检测包含240个点的肺癌组织芯片中KAI1、MRP-1和FAK蛋白的表达。结果:KAI1在肺癌原发灶中阳性率为25.9%,MRP-1为42.6%,与正常肺组织(100%)相比均显著下调;FAK蛋白在肺癌组织中阳性率为44.4%,与正常肺组织相比显著增高;KAI1、FAK两种蛋白在肺癌组织中的表达与患者的年龄、性别、肿瘤的大体类型及组织类型无关,而与肿瘤的分化程度、临床分期及是否伴有淋巴结转移密切相关,两种蛋白的表达呈显著负相关。MRP-1蛋白在肺癌组织中的表达与组织类型有关,小细胞肺癌与非小细胞肺癌相比差异显著,MRP-1与KAI1呈显著正相关,与FAK呈显著负相关。结论:KAI1、MRP-1和FAK的异常表达与肺癌的浸润转移有关,联合检测这3项指标对肺癌的发生发展有重要的预测作用。

康艾注射液联合化疗及贝伐珠单抗对晚期结直肠癌患者疗效及生存的影响

目的:探讨康艾注射液联合化疗及贝伐珠单抗对晚期结直肠癌(mCRC)患者疗效及生存的影响。方法:回顾性分析2018年6月~2021年12月芜湖市第一人民医院诊治的mCRC患者68例,分为A、B两组,A组34例给予康艾注射液联合CAPEOX方案(奥沙利铂+卡培他滨)及贝伐珠单抗一线方案治疗,B组34例予化疗及贝伐珠单抗一线方案治疗(方案同A组)。5周期治疗后,两组肿瘤未进展的患者,改为卡培他滨维持治疗至疾病进展。比较两组患者的疗效、血清肿瘤标志物的变化,采用生存分析比较两组患者的中位无进展生存期(mPFS)。结果:A组客观缓解率(67.6%)高于B组(41.2%)(P<0.05)。A组和B组5周期治疗后的CEA及CA199水平较治疗前均下降(P<0.001),且A组治疗前后的CEA及CA199水平下降幅度均高于B组(P<0.05)。A组的mPFS长于B组(P<0.05),两组病人骨髓抑制、恶心呕吐等不良反应发生率差异均无统计学意义(P>0.05)。结论:与CAPEOX方案联合贝伐珠单抗相比,mCRC患者行康艾注射液联合CAPEOX方案及贝伐珠单抗治疗,可以提高临床疗效、降低血清肿瘤标志物水平和延长mPFS,且未增加不良反应。

消癌平注射液对多西紫杉醇在大鼠体内的药代动力学及体外CYP450酶活性的影响研究

目的探讨消癌平注射液(XAP)对大鼠体内多西紫杉醇(DOC)药代动力学与体外细胞色素P450(CYP450)酶活性的影响。方法对24只SD雄性大鼠实施体内研究,随机分为A组(DOC对照组)、B组(XAP+DOC组)、C组[(咪达唑仑(MDZ)对照组)]、D组(XAP+MDZ组)共4组。借助超高效液相色谱串联质谱法检测给药后5、10、20、30 min和1、2、3、4、6、8、12、24 h大鼠血清中DOC/MDZ浓度,计算药代动力学参数。通过重组CYP450酶3A4(CYP3A4)的体外反应体系展开研究,制备人肝微粒体,以MDZ为底物探究XAP对CYP450酶活性的抑制作用,考察XAP对DOC代谢的影响。结果体内药代动力学结果显示,XAP可使DOC的C max和AUC 0→t分别增加150%(P<0.01)和60%(P<0.05);t 1/2和MRT分别为(4.24±1.78)h、(3.92±1.14)h,较DOC对照组显著延长;XAP可使MDZ的消除延长,半衰期t 1/2延长至(0.962±0.19)h,MRT延长至(1.008±0.13)h,药时曲线下面积(AUC 0→∞)为(1510.078±242.11)ng·h/ml,均显著高于MDZ对照组(P<0.05)。以MDZ为底物进行的体外抑制实验表明,XAP(10~100 mg/ml)和C 21总甾体提取物(10~50μg/ml)能明显抑制人肝微粒体CYP3A4活性。结论XAP与DOC联合使用后,DOC的血药浓度升高,DOC的多个药代动力学参数明显改变,XAP对DOC的消除有抑制效能,同时其作用机制可能与CYP3A4受抑制有关。

乳腺浸润性小叶癌中E-cadherin和KAI1的表达及临床意义

目的检测抗癌1基因(Kang Ai 1,KAI1)和上皮性钙粘蛋白(E-cadherin,E-cad)在乳腺浸润性小叶癌(ILC)中的表达,并分析其临床病理学意义。方法应用免疫组织化学PV-9000法检测66例乳腺浸润性小叶癌及30例良性病变组织中KAI1和E-cadherin的表达情况。结果KAI1、E-cadherin在乳腺浸润性小叶癌与良性病变中的表达差别有统计学意义(P<0.05)。ILC中KAI1的表达与患者年龄及组织学分级有关(P<0.05),E-cadherin的表达与组织学分级有关(P<0.05),而与临床分期及淋巴结转移等其他临床病理因素无关(P>0.05)。结论KAI1和E-cadherin在癌组织中的阳性表达低于良性乳腺组织。KAI1和E-cadherin在乳腺浸润性小叶癌中的表达与肿瘤的分化程度有关。

氯吡格雷与丹参川芎嗪注射液联合亚低温对急性缺血性脑卒中（AIS）患者神经功能等方面的影响

目的评价探究氯吡格雷与丹参川芎嗪注射液联合亚低温对急性缺血性脑卒中(acuteischemicstroke,AIS)患者神经功能等方面的影响。方法选取该院于2017年12月—2019年3月收治的急性缺血性脑卒中(AIS)患者64例进行观察研究,按照治疗方式的不同分成两组,每组32例,接受氯吡格雷联合亚低温治疗的患者作为对照组,对照组基础上联合丹参川芎嗪注射液治疗的为观察组,比较两组患者的神经功能评分、治疗效果、生活能力及残障程度情况。结果治疗后观察组的临床总有效率(96.88%)显著高于对照组(75.00%),差异有统计学意义(χ^2=6.3354,P=0.0118),相比治疗前,治疗后两组患者的神经功能评分和残障程度显著下降,其生活活动能力评分显著提升,并且观察组患者的NIHSS评分(9.79±2.11)分、mRS评分(1.11±0.56)分以及BI指数(68.95±6.88)与对照组[(13.87±3.22)分、(1.89±0.77)分、(51.29±6.11)]相比较差异有统计学意义(t=5.9952、4.6343、10.8570,P<0.05)。结论临床治疗急性缺血性脑卒中采用氯吡格雷与丹参川芎嗪注射液联合亚低温的疗效更确切,可有效提升患者的神经功能,值得应用借鉴。

论嵇康对儒家乐教的解构

嵇康《声无哀乐论》的所有论点,其实皆根基于音乐的本质是气这一观念。首先,音乐是天地和合过程中禀气而生成的客观物质,能独立于人而存在。人自身的情感,无法影响到音乐所具备的客观独立性。其次,音乐与人情感的关系是,旋律节奏的“舒急”会使人产生“躁静”之反应。人一旦进入“躁静”状态便会失去平和,从而将事先已积压在内心但并未表现出来的情感状态进行显露。音乐的教化作用、道德意义只表现在是否能帮助人实现平和,这也是雅乐与郑声的根本区别。最后,嵇康与儒家皆提倡以乐为教,二者的分歧主要体现在对乐这一概念的定义上。嵇康并不否定乐教的价值,而是要对究竟什么是乐,音乐与人内在究竟存在什么关系,如何具体实现乐教等根本问题提出异议。嵇康试图以一种符合于其持有的气化宇宙论、自然哲学的音乐观念与乐教主张取代儒家乐教,这是其“越名教而任自然”的一种表现。

康艾注射液联合化疗对胃癌疗效的Meta分析

目的:探讨康艾注射液联合化疗治疗胃癌在临床疗效方面是否优于单独化疗方案。方法:全面收集2005-2012年PubMed、中国期刊全文数据库、中文科技期刊全文数据库、中国生物医学文献光盘数据库发表的康艾注射液联合化疗治疗胃癌的临床随机对照试验(randomized controlled trial,RCT),采用Stata软件进行数据处理和Meta分析。结果:共有14项RCT纳入Meta分析,与单用化疗相比,康艾注射液联合化疗在改善胃癌患者生活质量(P=0.000)、白细胞降低(P=0.000)、肠胃反应(P=0.000)、肝功损害(P=0.047)、周围神经系统损伤(P=0.000)、体质量降低(P=0.002)及疼痛(P=0.017)方面作用明显,而在临床有效率(P=0.093)及其他不良反应方面的差异无统计学意义。结论:基于现有临床证据,康艾注射液联合化疗治疗胃癌可提高患者生活质量、减轻化疗的部分不良反应。

康艾注射液联合肝动脉化疗栓塞术治疗原发性肝癌36例临床观察

目的:观察康艾注射液联合经导管动脉内化疗栓塞术(transcatheter arterial chemoembolization,TACE)治疗肝癌的临床疗效。方法:将67例患者随机分为2组,观察组36例与对照组31例,均采用相同的TACE治疗,观察组同时联合康艾注射液治疗。观察比较2组的疗效,KPS评分变化、体质量和不良反应发生情况。结果:观察组与对照组近期疗效分别为44.4%和41.9%,差异无统计学意义(P>0.05);观察组治疗前后KPS评分值上升,经比较差异有统计学意义(P<0.05),且对照组治疗后KPS评分值下降,治疗前后经比较差异无统计学意义(P>0.05);2组患者治疗前后体质量均无明显变化(P>0.05);观察组不良反应(包括白细胞减少、血红蛋白下降、肝功能损害等)发生率比对照组低,且差异有统计学意义(P<0.05)。而在血少板减少和恶心呕吐发生率及肾功能损害等不良反应的发生率方面,2组间差异无统计学意义(P>0.05)。结论:康艾注射液联合TACE治疗原发性肝癌,可以提高患者的生活质量,并减轻化疗的一些不良反应。

康艾注射液联合化疗治疗胰腺癌癌因性疲劳

目的:观察康艾注射液联合化疗治疗胰腺癌患者癌因性疲劳的临床疗效。方法:将28例胰腺癌患者半随机分为治疗组和对照组,分别给予康艾注射液联合化疗和单纯化疗治疗,观察并比较两组的治疗效果。结果:治疗组与对照组在疲劳症状评分、体力状况、生活质量改善方面的差异均具有统计学意义(P<0.05),不良反应较对照组轻(P<0.05)。结论:康艾注射液可有效减轻癌症患者相关疲劳症状,改善体力状况,减轻化疗的毒副反应。

非小细胞肺癌患者术后化疗结合中医辅助治疗的中期疗效观察

目的:观察非小细胞肺癌(NSCLC)患者术后GP方案(吉西他滨+顺铂)化疗联合康艾注射液和八珍颗粒中医辅助治疗的中期疗效。方法:按随机数字表法将符合标准的114例患者分为观察组和对照组,观察组48例,对照组66例。对照组术后采用GP方案化疗和对症支持治疗,观察组术后采用GP方案联合康艾注射液和八珍颗粒治疗。4个疗程后比较患者的治疗有效率、生活质量、化疗不良反应以及机体免疫功能。结果:观察组1年期生存率91.67%,2年期生存率68.75%,3年期生存率31.25%。对照组1年期生存率77.27%,2年期生存率46.97%,3年期生存率27.27%。两组比较,1年期和2年期生存率差异均有显著性意义(P<0.05),3年期生存率差异无统计学意义(P>0.05)。治疗后T淋巴细胞亚群比较,两组差异有非常显著性意义(P<0.01)。观察组生活质量改善率56.25%,对照组改善率24.24%,两组比较,差异有显著性意义(P<0.05)。两组患者均出现不同程度不良反应,观察组总发生率77.08%,对照组总发生率100%。两组比较,差异有显著性意义(P<0.05)。不良反应以消化道症状、发热和白细胞降低为主。结论:NSCLC患者术后GP方案化疗过程中联合中药康艾注射液和八珍颗粒,可减轻化疗产生的不良反应,增强患者免疫功能,提高生活质量。

康艾注射液在肿瘤姑息治疗中的临床研究现状

目的:收集2014年12月之前国内国外发表的关于康艾注射液姑息治疗晚期恶性肿瘤的随机对照试验文献,利用系统评价的方法评价康艾注射液在晚期恶性肿瘤姑息治疗中的疗效和安全性。方法:全面检索MEDLINE(Pubmed)、Cochrane library、中国生物医学文献数据库(CBM)、维普中文科技期刊数据库(VIP)、中国期刊全文数据库(CNKI)、万方数据库以得到康艾注射液姑息治疗晚期恶性肿瘤的合适文献,并采用Cochrane协作网提供的Rev Man 5.2软件对数据进行处理。结果:共纳入8个RCT,545例,文献质量均较低。对KPS评分改善情况进行meta分析,异质性检验(χ2=12.12,P=0.06,I2=51%),采用随机效应模型统计分析,治疗组优于对照组(RR=2.69,Z=4.54,P<0.000 01,95%CI=[1.75,4.12]);采用描述性统计方法分析,改善纳差症状方面共有4个研究,其中3个研究提示治疗组优于对照组。减轻疼痛方面共纳入6个试验,其中4个试验提示康艾注射液有利于减轻癌痛。康艾注射液姑息治疗在改善乏力症状和改善睡眠方面,结果均提示优于对照组。结论:康艾注射液在姑息治疗晚期恶性肿瘤方面,能够改善患者纳差、癌痛、乏力、失眠不适症状,并提高患者生活质量,但因纳入文献质量较低,需要更多更规范的RCT予以进一步印证。

肝癌合剂姑息疗法联合康艾注射液对晚期肝癌患者的疗效及生存分析

目的：探讨分析康艾注射液和肝癌合剂姑息疗法对晚期肝癌患者的疗效及生存情况的影响。方法：选择医院收治的92例中晚期肝癌患者,将其随机分为观察组48例、对照组44例,对照组患者给予康艾注射液及对症治疗,观察组患者在对照组基础上运用肝癌合剂治疗,两组均连续治疗60 d进行疗效评价,观察两组患者临床疗效、治疗前后T淋巴细胞亚群变化以及患者随访生存情况。结果：观察组患者治疗改善率64.58%、对照组患者治疗改善率43.18%,两组比较差异具有统计学意义（P〈0.05）;治疗后两组患者CD4^＋、CD4^＋/CD8^＋水平显著升高（P〈0.05）,而CD8^＋水平显著降低（P〈0.05）,且观察组患者变化程度显著优于对照组（P〈0.05）;观察组患者生存情况显著优于对照组（P〈0.05）。结论：肝癌合剂联合康艾注射液姑息疗法治疗晚期肝癌能够有效提高临床治疗总有效率,增强机体免疫功能,且有助于患者生存时间的延长,值得临床推广。